Thu, Dec 14, 2017 08:30 CET Lund, 14th December 2017 – SenzaGen (Nasdaq First North: SENZA) today reports highly positive results from the final laboratory stage in the validation of GARDskin™. The results form an important part of the evidence in the approval process for the validation by ECVAM and OECD International Regulatory Authorities. In […]

Tue, Oct 10, 2017 11:00 CET Lund, 10th October 2017 – SenzaGen (Nasdaq First North: SENZA) today announces positive results from an evaluation of GARDprotein, a test method which is developed to make it possible to eliminate allergenic proteins from today’s and tomorrow’s foodstuffs. GARDprotein has the potential to open up a new market for […]

Fri, Sep 08, 2017 08:30 CET SenzaGen announces today that the company will be presenting two scientific abstracts and hold a presentation titled “21st century testing: Can one test be stand alone?” at the upcoming EUROTOX Congress in Bratislava, Slovakia. The 53rd European Congress of the European Societies of Toxicology, EUROTOX, is to be held in […]